Strengthening Families & Communities LLC Takes $688,000 Position in Natera, Inc. $NTRA

Strengthening Families & Communities LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 4,275 shares of the medical research company’s stock, valued at approximately $688,000.

Other institutional investors have also modified their holdings of the company. Integrated Wealth Concepts LLC grew its stake in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its stake in shares of Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth raised its holdings in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Natera during the 2nd quarter valued at $298,000. Finally, Truist Financial Corp grew its holdings in Natera by 14.3% during the 2nd quarter. Truist Financial Corp now owns 36,248 shares of the medical research company’s stock worth $6,124,000 after acquiring an additional 4,525 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Barclays boosted their price objective on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Morgan Stanley increased their target price on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. Finally, Wells Fargo & Company raised their price objective on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Natera Trading Down 1.5%

Shares of NASDAQ NTRA opened at $227.68 on Wednesday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The company has a market cap of $31.49 billion, a price-to-earnings ratio of -99.42 and a beta of 1.64. The stock’s 50 day simple moving average is $235.58 and its 200 day simple moving average is $195.67.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same period in the prior year, the business earned ($0.26) earnings per share. Natera’s quarterly revenue was up 34.7% on a year-over-year basis. As a group, equities analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 71,932 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68. Following the completion of the transaction, the chief executive officer directly owned 217,354 shares of the company’s stock, valued at $51,021,677.96. This represents a 24.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Roelof Botha sold 75,000 shares of Natera stock in a transaction on Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the sale, the director directly owned 1,154,198 shares in the company, valued at $272,529,231.76. The trade was a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 350,703 shares of company stock worth $82,221,116 in the last quarter. 5.63% of the stock is currently owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.